中药对萎缩性胃炎异型增生的干预治疗

Interference Therapy in Chronic Atrophic Gastritis with Atypical Hyperplasia by Traditional Chinese Medicine

目的:探讨萎胃康对萎缩性胃炎(CAG)伴异型增生(ATP)的临床症状、CAG及ATP上皮病理改变的影响。方法:将胃镜和胃粘膜活检病理组织学确诊的172例CAG伴ATP的患者,随机分为治疗组和对照组。将萎胃康与维酶素两种药物分别制成Ⅰ、Ⅱ号胶囊,外观及大小相同,治疗组给予Ⅰ号胶囊,6粒/次,3次/d;对照组给予Ⅱ号胶囊,6粒/次,3次/d。两组均以3个月为1个疗程。观察临床症状改善情况,治疗前后1周内各做1次胃镜检查,在同一部位取材做病理组织学检查,检测血、尿、粪常规及肝、肾功能。结果:临床症状改善:治疗组总有效率88.51％(77/87),对照组64.71％(55/85)(P<0.01);ATP:治疗组总有效率78.17％(68/87),对照组为30.59％(26/85)(P<0.01);CAG:治疗组总有效率80.46％(70/87),对照组为41.18％(35/85)(P<0.01)。结论:萎胃康可以改善CAG伴ATP患者临床症状;对CAG及ATP有逆转作用,提示中药有干预CAG伴ATP进程的作用。

Objective: To study the influence of Weiweikang on clinical symptoms and epithelial pathology of chronic atrophic gastritis (CAG) with atypical hyperplasia (ATP). Methods:One hundred and seventy-tow patients of CAG with ATP were randomly divided into two groups by the result of gastroscope and gastric mucosa pathology. Weiweikang and Weimeimei were made into capsule No. 1 and No. 2 respectively. No. 1 was given to treatment group and No. 2 to control group, 6 capsules every time and 3 times every day. The treatment lasted for three months. The change of clinical symptom and gastric mucosa pathology were observed. Results: The total effective rate of clinical symptom was 88. 51 %( 77/87) in treatment group, 64. 71 % (55/85) in control group ( P <0. 01 ), and that of ATP was 78. 17 % (68/87) in treatment group, and 30. 59 % (26/85) in control group( P <0. 01), and that of CAG was 80. 46 % (70/87) in treatment group,and 41. 18 % (35/ 85) in contrast group( P <0.01). Conclusion: Weiweikang could improve the clinical symptom and gastric mucosa pathology of patients with CAG with ATP, which indicated that traditional Chinese medicine could intervene the development of the CAG with ATP.